TABLE 3.

The laboratory test biomarker combinations that significantly improved discrimination for both ischemic and bleeding risks when incorporated into DAPT score.

Biomarker combination				N	Predicted events	C (old)	C (new)	P	NRI	P	IDI	P
Ischemia-associated		Bleeding-associated
biomarker		biomarker
Name	Value	Name	Value
AST	1 (> ULN) 0 (≤ ULN and ≥ LLN) -1 (< LLN)	RDW-CV	1 (> ULN) 0 (≤ ULN and ≥ LLN) -1 (< LLN)	3,558	Ischemia	0.590 (0.560–0.610)	0.600 (0.580–0.620)	0.040	0.118 (0.028–0.175)	0.016	0.005 (0–0.011)	0.048
					Bleeding	0.560 (0.530–0.590)	0.580 (0.550–0.610)	0.030	0.090 (0.004–0.150)	0.032	0.004 (0.001–0.009)	<0.001

Reported P-values were corrected using Benjamini-Hochberg method to account for multiple hypothesis testing. N, sample size; C (old), C statistic of DAPT score; C (new), C statistic of DAPT score plus incorporated biomarker combination. NRI, net reclassification improvement; IDI, integrated discrimination improvement; ULN, upper limit of reference range; LLN, lower limit of reference range; AST, aspartate aminotransferase; RDW-CV, red cell distribution width coefficient of variation.